Michael D. Ezekowitz

Headshot of Michael D. Ezekowitz

Affiliated Clinical

Clinical Professor

Contact Us

ezekowitzm@mlhs.org
View Google Scholar to learn more

About

  • 2005 to 2010: Professor & Vice President, Lankenau Institute for Medical Research
  • 2005 to 2010: Vice President, Clinical Research, Main Line Hospitals
  • 2005 to present: Attending Cardiologist, Lankenau, Bryn Mawr & Paoli Hospitals

Publications

  • Residual Stroke Risk Among Patients With Atrial Fibrillation Prescribed Oral Anticoagulants: A Patient-Level Meta-Analysis From COMBINE AF. Johnson LS, Benz AP, … Ezekowitz M, et al. J Am Heart Assoc. 2024 Aug 27:e034758. doi: 10.1161/JAHA.123.034758
  • Emergency department visit for atrial fibrillation: sex differences in treatment and outcomes in the Global RE-LY AF Registry. Johnson LS, Jiang Y, … Ezekowitz MD, et al. Eur Heart J. 2024 Jun 4:ehae319. doi: 10.1093/eurheartj/ehae319
  • Estimating Vitamin K Antagonist Anticoagulation Benefit in People With Atrial Fibrillation Accounting for Competing Risks: Evidence From 12 Randomized Trials. Shah SJ, van Walraven C, … Ezekowitz MD, et al. Circ Cardiovasc Qual Outcomes. 2024 Mar 25:e010269. doi: 10.1161/CIRCOUTCOMES.123.010269
  • Retrospective Comparison of Patients ≥ 80 Years With Atrial Fibrillation Prescribed Either an FDA-Approved Reduced or Full Dose Direct-Acting Oral Anticoagulant. Taoutel R, Ezekowitz MD, Chaudhry UA, Weber C, Hassan D, … Kamareddine MH, Horn BI, Harper GR. Int J Cardiol Heart Vasc. 2022 Oct 10;43:101130. doi: 10.1016/j.ijcha.2022.101130
  • Residual Stroke Risk Despite Oral Anticoagulation in Patients with Atrial Fibrillation. Carlisle MA, Shrader P, … Kowey PR, … Ezekowitz, MD, et al. Heart Rhythm O2, 28 Sept 2022. https://doi.org/10.1016/j.hroo.2022.09.018
  • Drug Interactions Affecting Oral Anticoagulant Use. Mar PL, Gopinathannair R, … Ezekowitz MD, … the American Heart Association Electrocardiography & Arrhythmias Committee of the Council of Clinical Cardiology. Circ Arrhythm Electrophysiol. 2022 Jun;15(6):e007956.
  • Drug Interactions Affecting Antiarrhythmic Drug Use. Mar PL, Horbal P, … Ezekowitz M, et al. Circ Arrhythm Electrophysiol. 2022 May 2:101161CIRCEP121007955. doi: 10.1161/CIRCEP.121.007955
  • Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. Liu HH, Ezekowitz MD, Columbo M, Khan O, Martin J, Spahr J, Yaron D, Cushinotto L, Kapelusznik L.J Interv Card Electrophysiol. 2022 Mar;63(2):345-356.
  • Direct Oral Anticoagulants versus Warfarin in Patients with Atrial Fibrillation: Patient-Level Network Meta-Analyses of Randomized Clinical Trials with Interaction Testing by Age and Sex. Carnicelli AP, Hong H, … Ezekowitz M, et al. Circulation. 2022 Jan 25;145(4):242-255.
  • Using multimarker screening to identify biomarkers associated with cardiovascular death in patients with atrial fibrillation. Pol T, Hijazi Z, … Ezekowitz MD, et al. Cardiovasc Res. 2022 Jul 20;118(9):2112-2123.
  • Millenaar D, Schumacher H, … Ezekowitz M, et al. Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Am J Cardiol. 2021 Jun 15;149:27-35.
  • Comparison of Low-Dose Direct Acting Anticoagulant and Warfarin in patients Aged ≥80 years With Atrial Fibrillation. Chaudhry UA, Ezekowitz MD, Gracely EJ, George WT, Wolfe CM, Harper G, Harper GR. Am J Cardiol. 2021 Aug 1;152:69-77.
  • Predictors of sinus rhythm 6 weeks after cardioversion of atrial fibrillation: a pre-planned post hoc analysis of the X-VeRT trial. Cappato R, Ezekowitz MD, Hohnloser SH, et al. Europace. 2021 Oct 9;23(10):1539-1547.
  • Testing the feasibility of operationalizing a prospective, randomized trial with remote cardiac safety EKG monitoring during a pandemic. Liu HH, Ezekowitz MD, Columbo M, et al. J Interv Card Electrophysiol. 2021 May 26:1-12.
  • Cardiovascular Outcomes According to Polypharmacy and Drug Adherence in Patients with Atrial Fibrillation on Long-Term Anticoagulation (from the RE-LY Trial). Millenaar D, Schumacher H, … Ezekowitz M, et al. Am J Cardiol. 2021 Mar 20:S0002-9149(21)00267-8.
  • Stroke risk prediction in patients with atrial fibrillation with and without rheumatic heart disease. Benz AP, Healey JS, Chin A, …, Ezekowitz MD, et al. Cardiovasc Res. 2022 Jan 7;118(1):295-304.
  • Screening of Multiple Biomarkers Associated With Ischemic Stroke in Atrial Fibrillation. Hijazi Z, Wallentin L, Lindbäck J, … Ezekowitz MD, et al. J Am Heart Assoc. 2020 Dec 15;9(24):e018984.
  • Evaluation of the Age, Biomarkers, and Clinical History-Bleeding Risk Score in Patients With Atrial Fibrillation With Combined Aspirin and Anticoagulation Therapy Enrolled in the ARISTOTLE and RE-LY Trials. Hijazi Z, Oldgren J, … Ezekowitz M, et al. JAMA Netw Open 2020 Sep 1;3(9):e2015943
  • Differences in Thromboembolic Complications Between Paroxysmal and Persistent Atrial Fibrillation Patients Following Electrical Cardioversion (From the ENSURE-AF Study). Goette A, Lip GYH, Jin J, Heidbuchel H, Cohen AA, Ezekowitz M, Merino JL. Am J Cardiol. 2020 Jun 30:S0002-9149(20)30623-8.
  • Patterns of oral anticoagulation use with cardioversion in clinical practice. Geurink K, Holmes D, Ezekowitz MD, Pieper K, Fonarow G, Kowey PR, et al. Heart. 2020 Jun 26:heartjnl-2019-316315.
  • Shared Decision Making in Atrial Fibrillation: Patient-Reported Involvement in Treatment Decisions. Ali-Ahmed F, Pieper K, North R, Allen LA, Chan PS, Ezekowitz MD, … Kowey PR, et al. Eur Heart J Qual Care Clin Outcomes. 2020 May 11:qcaa040. doi: 10.1093/ehjqcco/qcaa040.
  • Cardiovascular outcomes, bleeding risk, and achieved blood pressure in patients on long-term anticoagulation with the thrombin antagonist dabigatran or warfarin: data from the RE-LY trial. Böhm M, Brueckmann M, Eikelboom JW, Ezekowitz M, et al. Eur Heart J. 2020 May 8:ehaa247. doi: 10.1093/eurheartj/ehaa247.
  • Factors Associated with Large Improvements in Health-Related Quality of Life in Patients with Atrial Fibrillation: Results from ORBIT-AF. Steinberg BA, Holmes DN, Pieper K, Allen LA, Chan PS, Ezekowitz MD, … Kowey PR, et al. Circ Arrhythm Electrophysiol. 2020 Apr 16. doi: 10.1161/CIRCEP.119.007775.
  • Left Ventricular Thrombi: Uncommon but Clinically Important. Ezekowitz MD, Kurz D, Kent A. J Am Coll Cardiol. 2020 Apr 14;75(14):1686-8.
  • Characteristics and outcomes of atrial fibrillation in patients without traditional risk factors: RE-LY AF registry analysis. Kloosterman M, Oldgren J, Conen D, … Ezekowitz MD, et al. Europace. 2020 Mar 26. pii: euz360.
  • Risk of major cardiovascular and neurologic events with obstructive sleep apnea among patients with atrial fibrillation. Dalgaard F, North R, Pieper K, Fonarow GC, Kowey PR, … Ezekowitz M, et al. Am Heart J. 2020 Jan 7;223:65-71.
  • Effects of Rivaroxaban on Biomarkers of Coagulation and Inflammation: A Post Hoc Analysis of the X-VeRT Trial. Kirchhof P, Ezekowitz MD, Purmah Y, et al. TH Open. 2020 Jan 23;4(1):e20-e32.
  • Hypertension prevalence but not control varies across the spectrum of risk in patients with atrial fibrillation: A RE-LY atrial fibrillation registry sub-study. McAlister FA, Mian R, Oldgren J, … Ezekowitz M, et al. PLoS One. 2020 Jan 15;15(1):e0226259.
  • Decline in renal function and oral anticoagulation dose reduction among patients with atrial fibrillation. Inohara T, Holmes DN, Pieper K, … Ezekowitz MD, Kowey PR, et al. Heart. 2020 Jan 7. pii: heartjnl-2019-315792.
  • Determinants of left atrium thrombi in scheduled cardioversion: an ENSURE-AF study analysis. Merino JL, Lip GYH, … Ezekowitz MD, et al. Europace. 2019 Aug 22. pii: euz213.
  • Treatment of atrial fibrillation with concomitant coronary or peripheral artery disease: Results from the outcomes registry for better informed treatment of atrial fibrillation II. Inohara T, Shrader P, Pieper K, … Ezekowitz MD, et al. Am Heart J. 2019 Jul;213:81-90.
  • Defining Clinically Important Difference in the Atrial Fibrillation Effect on Quality-of-Life Score. Holmes DN, Piccini JP, Allen LA, … Ezekowitz MD, et al. Circ Cardiovasc Qual Outcomes. 2019 May;12(5):e005358.

Education and training

Education

  • M.B.,Ch,B
    University of Cape Town
  • D. Phil.
    Imperial College, London University
  • Fellowship
    Johns Hopkins Hospital

Academic titles

  • 2005 to 2010: Professor & Vice President, Lankenau Institute for Medical Research
  • 2005 to 2010: Vice President, Clinical Research, Main Line Hospitals
  • 2005 to present: Attending Cardiologist, Lankenau, Bryn Mawr & Paoli Hospitals